Common weight reduction medicine together with Ozempic and Wegovy will carry a brand new warning a couple of attainable uncommon facet impact that may generally result in everlasting imaginative and prescient loss, U.S. well being regulators introduced Monday.
The Meals and Drug Administration stated the danger will likely be added to the labeling of all GLP-1 medicine, the blockbuster medicines used to deal with weight problems, diabetes and a number of other different medical circumstances. The category features a dozen injectable or pill-based medicine, together with broadly used manufacturers like Zepbound and Mounjaro.
The attention situation, referred to as non-arteritic anterior ischemic optic neuropathy, could cause vital imaginative and prescient loss. The issue, which has been reported with all GLP-1 medicine, is attributable to decreased blood movement to the optic nerve, though the underlying trigger is not understood, the FDA stated.
FDA scientists started wanting into the issue after the publication of a 2024 medical paper tying the situation to sure sufferers taking semaglutide, the lively drug in Eli Lilly’s Ozempic.
An FDA evaluation of greater than 125 scientific trials discovered that the issue occurred in roughly 6 of each 100,000 sufferers who took a GLP-1 for at the very least one 12 months. The comparable charge for folks taking a placebo or different sorts of glucose-lowering medicines was lower than 4 per 100,000, the FDA stated.
The company additionally discovered studies of the issue in its digital reporting system for drug accidents and unwanted side effects.
Signs of the issue embody blurred imaginative and prescient, blind spots, distorted colours and different visible disturbances, in line with the FDA. Sufferers experiencing such issues ought to contact a well being care skilled instantly, the company stated.
